ActRIIB: The Core Receptor in Muscle Homeostasis Regulation and a Novel Therapeutic Target for Diseases
Author: Senior Product Manager of UA Views：3 
This article systematically elaborates on the molecular characteristics and biological functions of activin receptor type IIB (ActRIIB), focusing on its expression features in skeletal muscle, cardiac muscle, and adipose tissue as a TGF-β superfamily receptor, as well as its high sensitivity to myostatin and activin B. It analyzes its therapeutic potential in muscle atrophy diseases, cancer cachexia, and metabolic disorders, along with the advantages and challenges of targeted drug development.
- Recent Advances
- Product Information
Recent Advances
ActRIIB: The Core Receptor in Muscle Homeostasis Regulation and a Novel Therapeutic Target for Diseases
Summary
This article systematically elaborates on the molecular characteristics and biological functions of activin receptor type IIB (ActRIIB), detailing its expression profile in skeletal muscle, cardiac muscle, and adipose tissue as a TGF-β superfamily receptor, as well as its high sensitivity to myostatin and activin B. It analyzes its therapeutic potential in muscle atrophy disorders, cancer cachexia, and metabolic diseases, along with the advantages and challenges in targeted drug development.
This article systematically elaborates on the molecular characteristics and biological functions of activin receptor type IIB (ActRIIB), detailing its expression profile in skeletal muscle, cardiac muscle, and adipose tissue as a TGF-β superfamily receptor, as well as its high sensitivity to myostatin and activin B. It analyzes its therapeutic potential in muscle atrophy disorders, cancer cachexia, and metabolic diseases, along with the advantages and challenges in targeted drug development.
1. Molecular Characteristics and Tissue Distribution of ActRIIB
Activin receptor type IIB (ActRIIB) is a type I single-pass transmembrane protein encoded by the ACVR2B gene, belonging to the serine/threonine kinase receptor family of the TGF-β superfamily. The gene is located on human chromosome 3p22.2, and the encoded receptor protein consists of an extracellular ligand-binding domain, a single transmembrane helix region, and an intracellular serine/threonine kinase domain. ActRIIB is highly expressed in skeletal muscle, cardiac muscle, and adipose tissue, a distribution pattern that underscores its central role in muscle growth, energy metabolism, and cardiovascular function regulation.
2. Ligand Binding Properties and Signal Transduction of ActRIIB
ActRIIB can bind with high affinity to multiple members of the TGF-β superfamily ligands, including activin A/B, myostatin (GDF-8), and growth differentiation factor 11 (GDF-11). ActRIIB exhibits higher sensitivity to activin B than activin A and serves as the primary signal transduction receptor for myostatin in muscle tissue. Upon ligand binding, ActRIIB undergoes conformational changes and dimerization, recruiting and phosphorylating type I receptors (e.g., ALK4) to activate the downstream SMAD2/3 signaling pathway, ultimately regulating target gene transcription. Compared to ActRIIA, ActRIIB-mediated signals are typically stronger in muscle tissue, a difference that forms the molecular basis for its role as a core regulator of muscle homeostasis.
3. Physiological Functions and Disease Associations of ActRIIB
The ActRIIB signaling pathway exerts a negative regulatory effect on skeletal muscle mass maintenance—its activation inhibits the activation of muscle satellite cells and hypertrophy of muscle fibers. Inhibiting ActRIIB can significantly increase muscle mass and strength. In metabolic regulation, ActRIIB signaling participates in systemic metabolic control by influencing fat metabolism and energy balance. In erythropoiesis, ActRIIB is involved in regulating iron metabolism and red blood cell production.
Based on these functions, ActRIIB has emerged as a therapeutic target for various diseases, including amyotrophic lateral sclerosis, Duchenne muscular dystrophy, cancer cachexia, obesity and type 2 diabetes, and anemia associated with myelodysplastic syndromes.
4. Advantages and Challenges in ActRIIB-Targeted Drug Development
The successful approval of luspatercept, an ActRIIB ligand trap, validates the druggability of the ActRIIB pathway. However, systemic inhibition of ActRIIB may carry risks such as excessive muscle growth leading to increased joint burden, impacts on cardiac structure and function, and polycythemia. The influence of individual differences on efficacy requires further investigation.
5. Conclusion
As a key receptor in the TGF-β superfamily, ActRIIB plays a central role in muscle homeostasis regulation due to its predominant expression in skeletal and cardiac muscle and its high sensitivity to myostatin and activin B. Its therapeutic potential in muscle atrophy disorders, cancer cachexia, and metabolic diseases has been preliminarily validated, and the successful approval of luspatercept further confirms the druggability of this target. Human ActRIIB recombinant protein, as a critical tool for basic research and drug development, will continue to provide essential support for in-depth analysis of the ActRIIB signaling network and optimization of related disease treatment strategies.
In ActRIIB-related basic research and drug screening, high-quality human ActRIIB recombinant protein is a core tool for ligand binding analysis, signaling pathway studies, and drug activity evaluation. To meet this research demand, Uni offers ACTRIIB His Tag Protein, Human, suitable for applications such as ActRIIB-ligand (e.g., activin B, myostatin) binding activity analysis, SMAD2/3 signaling pathway mechanism studies, and in vitro screening and evaluation of ActRIIB-targeting antibodies or small-molecule drugs.
This article is reviewed and published by the technical expert team of UA
Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.
Purchase recombinant protein, choose Nanjing UA-Bio
UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Youai is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.
Target proteins | membrane proteins | cytokines | enzymes | viral antigens | protein customization
Nanjing UA Biotechnology Co., Ltd. Email：order@ua-bio.com Phone：+86-25-56221161
Product Information
Link：
©2021-2026 all rights reserved UA Biotechnology Co.,Ltd.
Privacy Policy 
网站备案号 浙ICP备2022019033号-2 浙公网安备33010202004867号
Business license (three certificates in one) Tel：+86-25-56221161
E-mail：order@ua-bio.com
All products sold on this website shall not be used for clinical diagnosis or treatment of humans or animals, and shall only be used for non-medical purposes such as industrial or scientific research.
